3 Things to Take Away From Boston Scientific's Management Meetings

Needham & Company analyst, Mike Matson, reiterated his Buy rating on shares of Boston Scientific and raised his price target to $32 after hosting meetings with Susie Lisa, VP of Investor Relations, this week in Kansas City. Key Takeaways include:

1) Unlike competitors that use self- or balloon-expansion, Lotus uses mechanical expansion that enables it to be repositioned if necessary; BSX has seen this feature used in about 1/3 of cases.

2) BSX continues to view Watchman as a potential $500M product based on very conservative penetration assumptions; however, we wouldn't be surprised to see BSX increase this at next week's investor day since we estimate Watchman sales will exceed $200M in 2017.

Back to news